PMID- 31034270
OWN - NLM
STAT- MEDLINE
DCOM- 20190620
LR  - 20190620
IS  - 1943-5681 (Electronic)
IS  - 0002-9645 (Linking)
VI  - 80
IP  - 5
DP  - 2019 May
TI  - Effects of orally administered raltegravir in cats with experimentally induced 
      ocular and respiratory feline herpesvirus-1 infection.
PG  - 490-497
LID - 10.2460/ajvr.80.5.490 [doi]
AB  - OBJECTIVE: To determine the effects of orally administered raltegravir in cats 
      with experimentally induced ocular and respiratory feline herpesvirus-1 (FHV-1) 
      infection. ANIMALS: 14 healthy 6-month-old unvaccinated specific pathogen-free 
      cats. PROCEDURES: On day 0, all cats were experimentally inoculated by topical 
      application of 0.1 mL of a solution containing 10(6) plaque-forming units of 
      FHV-1 strain FH2CS to the inferior conjunctival fornix of each eye. Cats were 
      randomly assigned to receive either raltegravir (80 mg; n = 7) or lactose (250 
      mg; vehicle; 7), PO, every 12 hours for 14 days beginning on day 1. Cats were 
      assigned clinical ocular and respiratory disease scores every other day from days 
      0 to 30. Conjunctival swab specimens were collected for detection of FHV-1 by 
      virus isolation and real-time PCR assay at 3-day intervals from days 0 to 30. 
      Confocal microscopy was performed on days 0 and 10 to assess corneal epithelial 
      leukocyte infiltration. The assessed variables and duration of FHV-1 shedding 
      were compared between the 2 treatment groups. RESULTS: Cats in both groups 
      developed moderate to severe conjunctivitis and ulcerative keratitis 
      characteristic of FHV-1 infection. Median duration of FHV-1 shedding was shorter 
      and signs of ocular and respiratory disease were less severe for 
      raltegravir-treated cats than for vehicle-treated cats. However, the mean 
      conjunctival FHV-1 titer and corneal epithelial leukocyte count did not differ 
      between the 2 groups. CONCLUSIONS AND CLINICAL RELEVANCE: Results suggested 
      orally administered raltegravir might be effective for alleviation of ocular and 
      respiratory signs of FHV-1 infection in cats. (Am J Vet Res 2019;80:490-497).
FAU - Spertus, Chloe B
AU  - Spertus CB
FAU - Pennington, Matthew R
AU  - Pennington MR
FAU - Van de Walle, Gerlinde R
AU  - Van de Walle GR
FAU - Badanes, Zachary I
AU  - Badanes ZI
FAU - Judd, Bonnie E
AU  - Judd BE
FAU - Mohammed, Hussni O
AU  - Mohammed HO
FAU - Ledbetter, Eric C
AU  - Ledbetter EC
LA  - eng
PT  - Clinical Trial, Veterinary
PT  - Journal Article
PL  - United States
TA  - Am J Vet Res
JT  - American journal of veterinary research
JID - 0375011
RN  - 0 (Antiviral Agents)
RN  - 43Y000U234 (Raltegravir Potassium)
SB  - IM
MH  - Animals
MH  - Antiviral Agents/*therapeutic use
MH  - Cat Diseases/*drug therapy/virology
MH  - Cats
MH  - Conjunctivitis, Viral/drug therapy/*veterinary
MH  - Herpesviridae Infections/drug therapy/*veterinary
MH  - Raltegravir Potassium/*therapeutic use
MH  - Random Allocation
MH  - Respiratory Tract Infections/drug therapy/*veterinary/virology
MH  - Single-Blind Method
MH  - Specific Pathogen-Free Organisms
MH  - *Varicellovirus
EDAT- 2019/04/30 06:00
MHDA- 2019/06/21 06:00
CRDT- 2019/04/30 06:00
PHST- 2019/04/30 06:00 [entrez]
PHST- 2019/04/30 06:00 [pubmed]
PHST- 2019/06/21 06:00 [medline]
AID - 10.2460/ajvr.80.5.490 [doi]
PST - ppublish
SO  - Am J Vet Res. 2019 May;80(5):490-497. doi: 10.2460/ajvr.80.5.490.